In a 17-patient group, 82% responded to AbbVie’s investigational small-cell lung cancer drug.

AbbVie (NYSE: ABBV) will present data on seven oncology assets at the 2026 ESMO Congress, highlighting progress in lung, colorectal, ovarian, prostate, and gastric cancers. The data includes longer-term survival, combination, and biomarker findings across various stages of development.

AbbVie (ABBV) will present 20 new IBD treatment studies at UEG Week 2026, highlighting long-term data for risankizumab and upadacitinib. The company reports a 2.34% dividend yield, 85% payout ratio, and 5.2% 3-year dividend growth. ABBV's GF Score is 76/100, with strong profitability but moderate financial strength. Insiders sold $17.7M in shares over the past year, while guru ownership is evenly split between adding and trimming positions.

AbbVie (ABBV) presented 20 new IBD studies at UEG Week 2026, including long-term data for risankizumab and upadacitinib. Risankizumab showed 3-year remission rates of 54.0%-73.1% in UC. Upadacitinib maintained 4-year remission rates of 78.9%-86.6% in CD. Real-world data showed upadacitinib reduced hospitalizations and surgeries in IBD patients.

AbbVie presented 20 scientific abstracts at UEG Week 2026, highlighting long-term data for SKYRIZI and RINVOQ in treating inflammatory bowel disease (IBD). Key findings include sustained clinical and endoscopic remission rates for up to four years in Crohn's disease and ulcerative colitis. Additionally, real-world data showed positive outcomes for patients switching to upadacitinib. The company also shared new insights on risankizumab subcutaneous induction in Crohn's disease.

AbbVie presented interim results showing 70.2% of evaluable patients with moderate-to-severe Crohn's disease responded to upadacitinib within 12 weeks. Long-term data for risankizumab and upadacitinib in Crohn's and ulcerative colitis showed sustained clinical and endoscopic outcomes. New data on investigational therapy ABBV-466 was also presented at UEGW 2026.

AbbVie (ABBV) and Genmab reported positive Phase 3 trial results for epcoritamab plus R-CHOP in high-risk diffuse large B-cell lymphoma, showing a 51% reduction in disease progression or death risk. The data suggest potential for front-line treatment, supporting AbbVie's oncology ambitions and revenue diversification. Regulatory filings and approvals will be key next steps.